Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/25409 |
Resumo: | Cultural inequalities that are harmful to women can potentialize the risk of HIV in this group. The aim of this research was to draw the epidemiological and metabolic profile of women diagnosed with HIV. It consists in a cross-sectional analysis of a cohort study, performed in women living with HIV/AIDS that received antiretroviral therapy (ARV) and that were users of the Specialized Care Service in the municipality of Ponta Grossa – PR, between 2003 and 2018. The analysis was descriptive and the association between the medicines used and the metabolic changes were evaluated with relative risk (RR) and through the chi-squared test. Medical records of 451 women were analyzed: 80,5% were white, 44,4% were married, 88,2% contracted HIV by sexual transmission and 83,1% were heterosexual. There was significant association as a risk factor between the use of Protease Inhibitors (PI) and alterations on HDL cholesterol (RR = 1,70, IC95% 1,32-2,20 and p<0,01) and triglycerides levels (RR = 1,29, IC 95% 1,01-1,65 and p= 0,04). As a protective factor, there was a significant association between Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) and changes in HDL cholesterol levels (RR = 0,66, IC95% 0,53-0,82 and p<0,01). The study has shown association between ARV and metabolic changes in women, specially PI and NNRTI with HDL cholesterol and triglycerides, suggesting the necessity of other drug options for patients with higher cardiovascular risk. |
id |
UNIFEI_e1b884d0187c195d42dd827a481b4435 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/25409 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDSEfectos Metabólicos de la Terapia Antirretroviral en Mujeres que viven con HIV/AIDSEfeitos Metabólicos da Terapia Antirretroviral em Mulheres vivendo com HIV/AIDSHIVAIDSWomenAntiretroviralMetabolic.VIHSIDAMujeresAntirretroviralMetabólico.HIVAIDSMulheresAntirretroviralMetabólica.Cultural inequalities that are harmful to women can potentialize the risk of HIV in this group. The aim of this research was to draw the epidemiological and metabolic profile of women diagnosed with HIV. It consists in a cross-sectional analysis of a cohort study, performed in women living with HIV/AIDS that received antiretroviral therapy (ARV) and that were users of the Specialized Care Service in the municipality of Ponta Grossa – PR, between 2003 and 2018. The analysis was descriptive and the association between the medicines used and the metabolic changes were evaluated with relative risk (RR) and through the chi-squared test. Medical records of 451 women were analyzed: 80,5% were white, 44,4% were married, 88,2% contracted HIV by sexual transmission and 83,1% were heterosexual. There was significant association as a risk factor between the use of Protease Inhibitors (PI) and alterations on HDL cholesterol (RR = 1,70, IC95% 1,32-2,20 and p<0,01) and triglycerides levels (RR = 1,29, IC 95% 1,01-1,65 and p= 0,04). As a protective factor, there was a significant association between Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) and changes in HDL cholesterol levels (RR = 0,66, IC95% 0,53-0,82 and p<0,01). The study has shown association between ARV and metabolic changes in women, specially PI and NNRTI with HDL cholesterol and triglycerides, suggesting the necessity of other drug options for patients with higher cardiovascular risk.Las desigualdades culturales que son perjudiciales para las mujeres pueden potenciar el riesgo de contraer el VIH en este grupo. El objetivo de esta investigación fue trazar el perfil epidemiológico y metabólico de las mujeres diagnosticadas con VIH. Consiste en un análisis transversal de un estudio de cohorte, realizado en mujeres viviendo con VIH / SIDA que recibieron terapia antirretroviral (ARV) y que fueron usuarias del Servicio de Atención Especializada en el municipio de Ponta Grossa - PR, entre 2003 y 2018. El análisis fue descriptivo y la asociación entre los medicamentos utilizados y los cambios metabólicos se evaluó con el riesgo relativo (RR) y mediante la prueba de chi-cuadrado. Se analizaron las historias clínicas de 451 mujeres: el 80,5% eran blancas, el 44,4% estaban casadas, el 88,2% contrajo el VIH por transmisión sexual y el 83,1% eran heterosexuales. Hubo asociación significativa como factor de riesgo entre el uso de inhibidores de la proteasa (IP) y las alteraciones del colesterol HDL (RR = 1,70, IC95% 1,32-2,20 yp <0,01) y los niveles de triglicéridos (RR = 1,29, IC 95% 1,01-1,65 yp = 0,04). Como factor protector, hubo una asociación significativa entre los inhibidores de la transcriptasa inversa no nucleósidos (INNTI) y los cambios en los niveles de colesterol HDL (RR = 0,66, IC95% 0,53-0,82 yp <0,01). El estudio ha mostrado asociación entre ARV y cambios metabólicos en mujeres, especialmente IP y NNRTI con colesterol HDL y triglicéridos, lo que sugiere la necesidad de otras opciones de fármacos para pacientes con mayor riesgo cardiovascular.As desigualdades culturais prejudiciais às mulheres podem potencializar o risco à HIV para este grupo. O objetivo deste estudo foi traçar o perfil epidemiológico e metabólico de mulheres com HIV. Trata-se de um recorte transversal de estudo de coorte em mulheres vivendo com HIV/AIDS, em terapia antirretroviral (TARV) e que utilizavam o Serviço de Assistência Especializada de Ponta Grossa – PR entre 2003 e 2018. A análise foi descritiva e a associação entre esquema terapêutico e alterações metabólicas foi avaliada com risco relativo (RR) e teste de qui-quadrado. Foram analisados os prontuários de 451 mulheres, 80,5% brancas, 44,4% casadas, 88,2% contraíram HIV por transmissão sexual e 83,1% heterossexuais. Houve associação significativa como fator de risco entre uso de Inibidores da Protease (IP) e alterações no colesterol HDL (RR = 1,70, IC95% 1,32-2,20 e p<0,01) e triglicérides (RR = 1,29, IC 95% 1,01-165 e p= 0,04). Como fator protetor, houve associação significativa entre o uso de Inibidores da Transcriptase Reversa Não Nucleosídeos (ITRNN) e alterações no colesterol HDL (RR = 0,66, IC 95% 0,53-0,82 e p<0,001). O estudo mostrou associação entre o uso de TARV e alterações metabólicas nas mulheres, em especial os IP e ITRNN associado a colesterol HDL e triglicerídeos, sugerindo a necessidade de outras opções terapêuticas para pacientes de maior risco cardiovascular.Research, Society and Development2022-01-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2540910.33448/rsd-v11i1.25409Research, Society and Development; Vol. 11 No. 1; e58811125409Research, Society and Development; Vol. 11 Núm. 1; e58811125409Research, Society and Development; v. 11 n. 1; e588111254092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/25409/22220Copyright (c) 2022 Matheus Alves dos Santos; Erildo Vicente Muller; Camila Marinelli Martinshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSantos, Matheus Alves dosMuller, Erildo VicenteMartins, Camila Marinelli2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/25409Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:41.892643Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS Efectos Metabólicos de la Terapia Antirretroviral en Mujeres que viven con HIV/AIDS Efeitos Metabólicos da Terapia Antirretroviral em Mulheres vivendo com HIV/AIDS |
title |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
spellingShingle |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS Santos, Matheus Alves dos HIV AIDS Women Antiretroviral Metabolic. VIH SIDA Mujeres Antirretroviral Metabólico. HIV AIDS Mulheres Antirretroviral Metabólica. |
title_short |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
title_full |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
title_fullStr |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
title_full_unstemmed |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
title_sort |
Metabolic Effects of Antiretroviral Therapy in Women living with HIV/AIDS |
author |
Santos, Matheus Alves dos |
author_facet |
Santos, Matheus Alves dos Muller, Erildo Vicente Martins, Camila Marinelli |
author_role |
author |
author2 |
Muller, Erildo Vicente Martins, Camila Marinelli |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Santos, Matheus Alves dos Muller, Erildo Vicente Martins, Camila Marinelli |
dc.subject.por.fl_str_mv |
HIV AIDS Women Antiretroviral Metabolic. VIH SIDA Mujeres Antirretroviral Metabólico. HIV AIDS Mulheres Antirretroviral Metabólica. |
topic |
HIV AIDS Women Antiretroviral Metabolic. VIH SIDA Mujeres Antirretroviral Metabólico. HIV AIDS Mulheres Antirretroviral Metabólica. |
description |
Cultural inequalities that are harmful to women can potentialize the risk of HIV in this group. The aim of this research was to draw the epidemiological and metabolic profile of women diagnosed with HIV. It consists in a cross-sectional analysis of a cohort study, performed in women living with HIV/AIDS that received antiretroviral therapy (ARV) and that were users of the Specialized Care Service in the municipality of Ponta Grossa – PR, between 2003 and 2018. The analysis was descriptive and the association between the medicines used and the metabolic changes were evaluated with relative risk (RR) and through the chi-squared test. Medical records of 451 women were analyzed: 80,5% were white, 44,4% were married, 88,2% contracted HIV by sexual transmission and 83,1% were heterosexual. There was significant association as a risk factor between the use of Protease Inhibitors (PI) and alterations on HDL cholesterol (RR = 1,70, IC95% 1,32-2,20 and p<0,01) and triglycerides levels (RR = 1,29, IC 95% 1,01-1,65 and p= 0,04). As a protective factor, there was a significant association between Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) and changes in HDL cholesterol levels (RR = 0,66, IC95% 0,53-0,82 and p<0,01). The study has shown association between ARV and metabolic changes in women, specially PI and NNRTI with HDL cholesterol and triglycerides, suggesting the necessity of other drug options for patients with higher cardiovascular risk. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-16 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/25409 10.33448/rsd-v11i1.25409 |
url |
https://rsdjournal.org/index.php/rsd/article/view/25409 |
identifier_str_mv |
10.33448/rsd-v11i1.25409 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/25409/22220 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Matheus Alves dos Santos; Erildo Vicente Muller; Camila Marinelli Martins https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Matheus Alves dos Santos; Erildo Vicente Muller; Camila Marinelli Martins https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 1; e58811125409 Research, Society and Development; Vol. 11 Núm. 1; e58811125409 Research, Society and Development; v. 11 n. 1; e58811125409 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052792414666752 |